Latest News Archive
Please select Category, Year, and then Month to display items
11 January 2021
|
Story André Damons
|
Photo Supplied
Dr Ralph Clark
The Afromontane Research Unit (ARU), the flagship research group of the University of the Free State (UFS) Qwaqwa Campus, has recently been granted R8,4 million to establish a Risk and Vulnerability Science Centre programme.
The Risk and Vulnerability Science Centre (RVSC) programme was established by the Department of Science and Innovation (DSI) as part of the Global Change Research Plan for South Africa and is funded by the DSI through the National Research Foundation (NRF). The RVSC will focus on the need to generate and disseminate knowledge about risk and vulnerability on global change challenges faced by local policy makers/ governance structures and communities in South Africa.
Invited to participate
Dr Ralph Clark, Director of the ARU, says the UFS, together with the University of Zululand and the Sol Plaatje University, has been invited to participate in Phase 2 of the RVSC programme. Dr Clark was approached by the DSI (on referral from the South African Environmental Observation Network – SAEON) in February 2020 regarding the potential for establishing a RVSC at the UFS Qwaqwa campus.
Subsequent interactions were held between the UFS and DSI, and in March 2020, the UFS formally accepted the DSI invitation. It has since been agreed that the RVSC: UFS will be hosted as a RVSC under the ARU umbrella, with dedicated personnel embedded at the UFS in this regard (internal processes and reporting) but reporting directly to the NRF regarding the RVSC.
Interest and support welcomed
Dr Clark welcomed this interest and support from the DSI-NRF, saying that the funds will further assist the UFS in growing its excellent and growing research portfolio and building more research capacity on this traditionally undergraduate-focused campus. “The RVSC will contribute to much-needed solutions in an area marked by major sustainability challenges and will assist in moving Phuthaditjhaba away from its negative apartheid history towards becoming a sustainable African mountain city,” says Dr Clark.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004